MBOT · XBRL financial data

Microbot Medical financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MBOT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	3,396	6,153	7,736	5,724	6,630	6,283
Selling, general and administrative	—	—	—	—	4,995	8,460
General and administrative	5,693	5,204	5,545	4,131	4,995	—
Operating income (loss)	(9,089)	(11,357)	(13,281)	(9,855)	(11,625)	(14,743)
Other income (expense)	—	—	(5)	—	—	—
Income tax expense (benefit)	0	—	—	—	—	—
Net income (loss)	(9,169)	(11,313)	(13,168)	(10,740)	(11,443)	(13,142)
Earnings per share, basic USD per share	—	(1.59)	(1.81)	(1.05)	(0.73)	(0.29)
Earnings per share, diluted USD per share	—	—	(1.81)	(1.05)	(0.73)	(0.29)
Weighted average shares, basic thousands of shares	—	7,108	7,260	10,200	15,645	45,790
Weighted average shares, diluted thousands of shares	—	—	7,260	10,200	15,645	45,790

Fiscal years (MBOT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	19,650	13,493	2,442	2,468	3,114	3,912
Marketable securities	4,998	1,999	5,760	3,917	2,356	74,680
Inventory	—	—	—	—	—	584
Prepaid and other current assets	521	300	532	152	300	644
Total current assets	25,253	15,879	8,814	7,921	5,819	79,822
Property and equipment, net	251	244	221	146	80	93
Right-of-use asset	775	644	502	260	132	833
Total assets	26,279	16,767	9,537	8,327	6,031	81,544
Accounts payable	275	279	116	357	165	511
Accrued liabilities	883	1,427	1,670	1,027	2,225	2,614
Total current liabilities	1,345	1,984	2,069	3,786	2,460	3,421
Lease liability, non-current	626	402	179	40	41	569
Total liabilities	1,971	2,386	2,248	3,826	2,501	3,990
Accumulated deficit	(44,280)	(55,593)	(68,761)	(79,501)	(90,944)	(104,086)
Total stockholders' equity	24,308	14,381	7,289	4,501	3,530	77,554
Total liabilities and equity	26,279	16,767	9,537	8,327	6,031	81,544
Common shares outstanding (cover page) thousands of shares	7,108	7,108	8,131	14,399	34,744	67,158

Fiscal years (MBOT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(9,169)	(11,313)	(13,168)	(10,740)	(11,443)	(13,142)
Stock-based compensation	1,937	1,386	1,752	1,394	1,349	1,057
Depreciation and amortization	68	76	102	106	91	47
Net cash from operating activities	(7,252)	(9,354)	(11,549)	(8,533)	(8,827)	(13,046)
Purchases of property and equipment	91	69	84	33	25	60
Net cash from investing activities	(2,768)	3,200	(3,836)	1,973	1,537	(72,384)
Proceeds from issuing equity	—	—	4,324	6,558	7,936	86,239
Net cash from financing activities	(3,375)	—	4,324	6,558	7,936	86,240
Net change in cash	(13,395)	(6,154)	(11,061)	(2)	646	810

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Microbot Medical	3,152	241	(4,989)*	67.2M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Fonar	53,650	26,472	1,580*	not reported	—	Q3 FY26 10-QMar 31, 2026
Pulmonx	52,690	22,835	(3,183)*	43.6M	8.5 quarters	Q3 FY26 10-QSep 30, 2026
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
TriSalus Life Sciences	46,288	11,407	(10,129)*	61.6M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.